

# TABLE OF CONTENTS

## CHAPTER 1

### Introduction

## CHAPTER 2

### State Common Law Claims Based Upon Informational Defects

§ 2.01	Introduction . . . . .	2.01-2
§ 2.02	The Duty to Warn and Unavoidably Unsafe Product Doctrine . . . . .	2.02-1
[1]	Unavoidably Unsafe Products and Design Defects . . . . .	2.02-13
[2]	Prescription Medical Devices and Biologics as Unavoidably Unsafe Products . . . . .	2.02-15
[3]	Case-by-Case Versus Categorical Application of the Unavoidably Unsafe Product Doctrine . . . . .	2.02-23
§ 2.03	The Learned Intermediary Rule . . . . .	2.03-1
[1]	The Learned Intermediary Rule as the Distinctive Attribute of Litigation Involving Prescription Medical Products . . . . .	2.03-2
[2]	Who Is the Learned Intermediary? . . . . .	2.03-57
[3]	Exceptions to the Learned Intermediary Rule . . . . .	2.03-66
[a]	Over-the-Counter Drugs . . . . .	2.03-66
[b]	Mass Immunization Exception . . . . .	2.03-68
[c]	FDA-Mandated Patient Warning Exception . . . . .	2.03-72
[d]	Personal Choice Product Exception . . . . .	2.03-74
[e]	Direct-to-Consumer Marketing Exception . . . . .	2.03-78

	[f] FDA Recall Exception . . . . .	2.03-82
	[g] Financial and Other Prescriber Incentives Exception . . . . .	2.03-82
	[h] Miscellaneous Unrecognized Exceptions . . . . .	2.03-85
§ 2.04	Adequacy of Warnings . . . . .	2.04-1
	[1] Criteria for an Adequate Warning . . . . .	2.04-1
	[2] Establishing the Adequacy of a Warning as a Matter of Law . . . . .	2.04-59
§ 2.05	Establishing Causation in a Warning Case . . . . .	2.05-1
	[1] When an Inadequate Warning Is Non-Causal . . . . .	2.05-1
	[2] Issues of Fact Concerning Warning Causation . . . . .	2.05-45
	[3] The Presumption That an Inadequate Warning Is Causal . . . . .	2.05-60
	[4] Other Causation Issues in Warning Cases . . . . .	2.05-76
	[5] Miscellaneous Causation Issues in Warning Claims . . . . .	2.05-92
§ 2.06	Overpromotion and Negligent Marketing Claims . . . . .	2.06-1
§ 2.07	Implied Warranty Claims . . . . .	2.07-1
§ 2.08	Express Warranty Claims . . . . .	2.08-1
§ 2.09	Illegal Promotion and Marketing Claims . . . . .	2.09-1
§ 2.10	Duty to Warn Claims Involving Direct Patient Warnings . . . . .	2.10-1
§ 2.11	Warning Claims Brought by Prescribing Physicians . . . . .	2.11-1
§ 2.12	Public Policy Considerations Underlying the Unavoidable Unsafe Product Doctrine and the Learned Intermediary Rule . . . . .	2.12-1
§ 2.13	Fraud/Intentional Misrepresentation . . . . .	2.13-1
§ 2.14	Negligent Misrepresentation . . . . .	2.14-1
§ 2.15	State Consumer Protection Acts . . . . .	2.15-1
§ 2.16	Federal RICO Claims . . . . .	2.16-1

### CHAPTER 3

#### State Common Law Claims Based Upon Non-Informational Defects

§ 3.01	Introduction—Design Defect Claims . . . . .	3.01-2
§ 3.02	Claims Sounding In Strict Liability . . . . .	3.02-1
	[1] Strict Liability—Pleading and Merger of Other Causes of Action . . . . .	3.02-3

[2]	Elements of Strict Liability Claims Brought Under <i>The Restatement</i> ( <i>Second</i> ) of Torts § 402A . . . . .	3.02-12
[3]	Requirement of an Unreasonably Dangerous Product . . . . .	3.02-17
[a]	Consumer Expectations Test . . . . .	3.02-21
[b]	Risk-Utility Test . . . . .	3.02-28
[c]	Hybridization of Consumer Expectations and Risk-Utility Tests . . . . .	3.02-41
[d]	The Role of the Feasible Safer Alternative Design . . . . .	3.02-45
[e]	Injury Alone Is Not Sufficient to Establish an Unreasonably Dangerous Product . . . . .	3.02-70
[4]	The Unavoidably Unsafe Product Doctrine . . . . .	3.02-76
[a]	Relationship of the Unavoidably Unsafe Product Doctrine to Design Defect Claims . . . . .	3.02-76
[b]	Role of the Risk-Utility Test Under the Unavoidably Unsafe Product Doctrine . . . . .	3.02-91
[c]	Role of Feasible Safer Alternative Design Under the Unavoidably Unsafe Product Doctrine . . . . .	3.02-94
[5]	Requirements of Injury and Proximate Cause . . . . .	3.02-97
§ 3.03	Design Defect Claims Under the <i>Restatement</i> ( <i>Third</i> ) of Torts: <i>Products Liability</i> . . . . .	3.03-1
§ 3.04	Design Defect Claims Sounding in Negligence . . . . .	3.04-1
§ 3.05	Manufacturing Defects . . . . .	3.05-1
[1]	Introduction . . . . .	3.05-1
[2]	The <i>Restatement</i> Formulation of Manufacturing Defect . . . . .	3.05-15
[3]	Plaintiff's <i>Prima Facie</i> Manufacturing Defect Case . . . . .	3.05-18
[4]	Rebutting Plaintiff's <i>Prima Facie</i> Case of Manufacturing Defect . . . . .	3.05-28
§ 3.06	Medical Monitoring . . . . .	3.06-1
§ 3.07	Independent Duty to Test . . . . .	3.07-1
§ 3.08	Market Share Liability . . . . .	3.08-1
§ 3.09	Cognizable Injury . . . . .	3.09-1
§ 3.10	Miscellaneous Claims . . . . .	3.10-1
[1]	Duty to Recall . . . . .	3.10-1
[2]	Restitution/Unjust Enrichment . . . . .	3.10-6
[3]	Lanham Act . . . . .	3.10-18

[4]	Redhibition . . . . .	3.10-18
[5]	Failure to Train. . . . .	3.10-21
[6]	Intentional/Negligent Infliction of Emotional Distress . . . . .	3.10-23
[7]	Miscellaneous Federal Claims . . . . .	3.10-28
[8]	Miscellaneous State Law Claims. . . . .	3.10-32

## CHAPTER 4

### The Federal Framework

§ 4.01	What Litigators Need to Know About the FDA . . . . .	4.01-2
[1]	Introduction. . . . .	4.01-2
[2]	FDA Approval Processes for Prescription Medical Products . . . . .	4.01-3
[a]	Prescription Drugs . . . . .	4.01-9
[b]	Medical Devices . . . . .	4.01-24
[c]	Generic Drugs . . . . .	4.01-35
[d]	Biologics . . . . .	4.01-37
[e]	Biosimilars . . . . .	4.01-37
[f]	Combination Products . . . . .	4.01-39
[3]	Post-Approval FDA Regulation. . . . .	4.01-40
[4]	Off-Label Use. . . . .	4.01-54
§ 4.02	The Food, Drug and Cosmetic Act as a Source of Substantive Tort Law . . . . .	4.02-1
[1]	No Private Food, Drug and Cosmetic Act Right of Action. . . . .	4.02-1
[2]	Negligence <i>Per Se</i> and Related Doctrines . . . . .	4.02-12
[a]	General Negligence <i>Per Se</i> Principles Applicable to Prescription Medical Product Liability Litigation . . . . .	4.02-12
[b]	The Viability of Negligence <i>Per Se</i> Claims Based Upon Allegations of FDCA Violations . . . . .	4.02-26
[i]	Arguments in Favor of Allowing FDCA-Based Negligence <i>Per Se</i> . . . . .	4.02-27
[ii]	Arguments in Favor of Rejecting FDCA-Based Negligence <i>Per Se</i> . . . . .	4.02-33
[3]	Defenses to FDCA-Based Negligence <i>Per Se</i> Claims . . . . .	4.02-50
[a]	Defense on the Merits/No Violation . . . . .	4.02-50

## TABLE OF CONTENTS

ix

	[b] Non-Statutory Violations . . . . .	4.02-54
	[c] Imposition of Novel Duties . . . . .	4.02-59
	[d] Allegations Concerning the FDA Approval Process . . . . .	4.02-68
	[e] Violations of Vague or Generic Enactments . . . . .	4.02-72
	[f] Causation Issues in FDCA-Based Negligence <i>Per Se</i> . . . . .	4.02-79
§ 4.03	Impact of Medicare Secondary Payer Legislation . . . . .	4.03-1

## CHAPTER 5

### Federal Preemption as a Defense to Drug and Medical Device Litigation

§ 5.01	Express Preemption . . . . .	5.01-4
	[1] General Considerations Concerning Express Preemption . . . . .	5.01-4
	[2] Application of Express Preemption to Common Law Tort Claims . . . . .	5.01-8
	[3] Express Preemption and Medical Devices . . . . .	5.01-10
	[a] Express Preemption and Substantially Equivalent Devices: <i>Lohr</i> and its Progeny . . . . .	5.01-11
	[b] Express Preemption and Premarket Approved Devices: <i>Riegel</i> and its Progeny . . . . .	5.01-18
	[c] Express Preemption Issues Following <i>Riegel</i> and <i>Lohr</i> . . . . .	5.01-20
	[i] Preemption Issues Involving Multi-Component Device Systems . . . . .	5.01-33
	[ii] Violation, “Identity of Requirements,” or “Parallel” Claims . . . . .	5.01-37
	[iii] Effect of Off-Label Use/Promotion on Preemption . . . . .	5.01-82
	[iv] Other Claims Not Addressed by the Supreme Court . . . . .	5.01-92
	[v] Procedural and Pleading Issues Relating to PMA Medical Device Preemption . . . . .	5.01-107

	[d]	Express Preemption and Devices on the Market Through Other FDA Procedures . . . . .	5.01-131
		[i] Investigational Devices . . . . .	5.01-131
		[ii] PMA Supplement Devices . . . . .	5.01-138
		[iii] Product Development Protocol and Transitional Devices . . . . .	5.01-140
		[iv] Downclassified Devices . . . . .	5.01-141
		[v] Reclassified Devices . . . . .	5.01-141
		[vi] Combination Devices . . . . .	5.01-141
		[vii] Humanitarian Devices . . . . .	5.01-142
	[e]	Special Cases of Device-Specific Preemption by Regulation . . . . .	5.01-142
		[i] Tampon Warnings . . . . .	5.01-142
		[ii] Latex Glove Warnings . . . . .	5.01-145
		[iii] Contact Lens Care Products . . . . .	5.01-147
		[iv] Latex Condoms . . . . .	5.01-147
	[4]	Express Preemption and Prescription Drugs . . . . .	5.01-147
	[5]	Express Preemption and Vaccines . . . . .	5.01-148
	[6]	Express Preemption and Monograph (OTC) Drugs . . . . .	5.01-152
	[7]	Express Preemption and FDA Decisions Not to Regulate . . . . .	5.01-160
	[8]	Express Preemption and Informed Consent . . . . .	5.01-161
	[9]	Express Preemption and the PREP Act . . . . .	5.04-162
	[10]	Express Preemption and Discovery . . . . .	5.01-162
§ 5.02		Implied Preemption . . . . .	5.02-1
	[1]	Field Preemption . . . . .	5.02-1
	[2]	Conflict Preemption . . . . .	5.02-3
		[a] Conflict Preemption by Reason of Impossibility . . . . .	5.02-3
		[b] Conflict Preemption by Reason of Obstruction . . . . .	5.02-5
	[3]	Implied Preemption in Product Liability Litigation . . . . .	5.02-6
		[a] Effect on Implied Preemption of Express Preemption Clauses . . . . .	5.02-6
		[b] Effect on Implied Preemption of Express Saving Clauses . . . . .	5.02-8
	[4]	Implied Conflict Preemption in the FDCA Context . . . . .	5.02-9
		[a] Prescription Drug Labeling and Marketing . . . . .	5.02-9

## TABLE OF CONTENTS

xi

	[i] Background . . . . .	5.02-9
	[ii] The 2006 FDA Preemption	
	Preamble . . . . .	5.02-13
	[iii] <i>Wyeth v. Levine</i> . . . . .	5.02-17
	[iv] Merck Sharp & Dohme	
	<i>Corp. v. Albrecht</i> . . . . .	5.02-20
	[v] Implied Preemption of Tort	
	Claims Involving Prescription	
	Drugs After <i>Levine</i> and	
	<i>Albrecht</i> . . . . .	5.02-24
	[vi] Preemption Based on Likely or	
	Actual FDA Rejection of the	
	Relevant Warning. . . . .	5.02-32
	[vii] Preemption Based on	
	Unavailability of CBE/FDA	
	Prior Review Requirement. . .	5.02-53
	[viii] Preemption Based on	
	Interference with the FDCA	
	Regulatory Scheme. . . . .	5.02-80
	[b] Generic Drugs . . . . .	5.02-83
	[c] Fraud on the FDA . . . . .	5.02-111
	[d] Private FDCA Enforcement	
	Violation Claims . . . . .	5.02-135
	[e] Miscellaneous Implied Preemption	
	Situations . . . . .	5.02-152
	[i] Boxed Warnings . . . . .	5.02-152
	[ii] Off-label Promotion . . . . .	5.02-153
	[iii] Failure to Report to/Warn the	
	FDA. . . . .	5.02-157
	[iv] Monograph (OTC) Drugs. . . . .	5.02-168
	[v] Other Claims . . . . .	5.02-169
§ 5.03	Complete Preemption and Federal Question	
	Jurisdiction . . . . .	5.03-1

## CHAPTER 6

### Before Litigation Starts: Enhancing Chances for Success

§ 6.01	Introduction . . . . .	6.01-2
§ 6.02	From the Plaintiff's Perspective. . . . .	6.02-1
	[1] Factual and Legal Investigation. . . . .	6.02-1
	[2] The Internet . . . . .	6.02-2
	[a] Government Web Sites . . . . .	6.02-2
	[b] Nongovernment Web Sites . . . . .	6.02-4
§ 6.03	From the Defendant's Perspective . . . . .	6.03-1
	[1] Prophylactic Planning. . . . .	6.03-1
	[a] SOPs. . . . .	6.03-2

[b]	Document Management . . . . .	6.03-2
[c]	Regulatory and Good Clinical Practice Issues . . . . .	6.03-4
[d]	Review of Internal and External Documents . . . . .	6.03-4
[e]	Freedom of Information Act . . . . .	6.03-5
[f]	Marketing Issues . . . . .	6.03-5
[2]	Adverse Event Reporting . . . . .	6.03-7
[3]	Duty to Update Labeling . . . . .	6.03-10
[a]	Section 10 of the <i>Restatement</i> <i>(Third) of Torts</i> . . . . .	6.03-12
[b]	Other Causes of Action . . . . .	6.03-12
[4]	Duty to Warn Regarding Off-Label Use . . .	6.03-13
[5]	Recalls . . . . .	6.03-14
[a]	Consequences . . . . .	6.03-15
[b]	Planning for and Executing Recalls . . .	6.03-16
[6]	Clinical Studies . . . . .	6.03-18
[a]	Clinical Trial Registry . . . . .	6.03-19
[b]	Integrated Pharmaceutical Networks . . . . .	6.03-20
[c]	International Clinical Studies . . . . .	6.03-21
[d]	Remuneration . . . . .	6.03-21
[e]	Consent . . . . .	6.03-22
[f]	Termination of Clinical Studies . . . . .	6.03-25
[7]	“Expanded Access” . . . . .	6.03-27

## CHAPTER 7

### Class Actions

§ 7.01	Overview . . . . .	7.01-3
§ 7.02	Nature of the Certification Determination . . . . .	7.02-1
§ 7.03	Class Actions in Personal Injury Cases . . . . .	7.03-1
[1]	Tolling of the Statute of Limitations . . . . .	7.03-1
[2]	Settlement . . . . .	7.03-4
§ 7.04	Class Actions for Economic Loss . . . . .	7.04-1
[1]	Causes of Action . . . . .	7.04-1
[2]	Grounds for Dismissal of a Claim . . . . .	7.04-3
[a]	Injury in Fact . . . . .	7.04-3
[b]	Factual Causation . . . . .	7.04-5
[c]	Proximate Causation . . . . .	7.04-6
§ 7.05	The Elements of a Definable and Ascertainable Class Under Rule 23(a) . . . . .	7.05-1
[1]	Numerosity . . . . .	7.05-2
[2]	Commonality . . . . .	7.05-4



# TABLE OF CONTENTS

xiii

	[3] Typicality . . . . .	7.05-5
	[4] Adequacy of Representation . . . . .	7.05-11
§ 7.06	Criteria for Determining Whether a Mandatory Class Action Can Be Maintained Under Rule 23(b)(1) or Rule 23(b)(2) . . . . .	7.06-1
	[1] Overview . . . . .	7.06-1
	[2] Constitutional Issues . . . . .	7.06-2
	[3] Classes Based on Declaratory or Injunctive Relief Under Rule 23(b)(1)(A) . . . . .	7.06-4
	[4] The “Limited Fund” Class Under Rule 23(b)(1)(B) . . . . .	7.06-5
	[5] Medical Monitoring Classes Under Rule 23(b)(2) . . . . .	7.06-9
	[a] Medical Monitoring as Final Injunctive Relief . . . . .	7.06-10
	[b] Money Damages Cannot Predominate in Rule 23(b)(2) Class . . . . .	7.06-13
	[c] The Proposed Class Must Be Cohesive . . . . .	7.06-15
§ 7.07	Rule 23(b)(3) and Requirements of Predominance and Superiority . . . . .	7.07-1
	[1] Predominance . . . . .	7.07-1
	[a] Problems Inherent in Proposed Nationwide Classes . . . . .	7.07-1
	[b] Other Individual Issues . . . . .	7.07-4
	[2] Superiority . . . . .	7.07-6
	[3] Manageability . . . . .	7.07-10
§ 7.08	The Potential for Certification on a Particular Issue . . . . .	7.08-1
§ 7.09	Federal Jurisdiction Over Class Actions—The Class Action Fairness Act (CAFA) . . . . .	7.09-1
	[1] Overview . . . . .	7.09-1
	[2] Existing Federal Question and Diversity Jurisdiction Unchanged . . . . .	7.09-1
	[3] Grounds for Diversity Jurisdiction . . . . .	7.09-3
	[a] \$5 Million Amount in Controversy Requirement . . . . .	7.09-3
	[b] Minimal Diversity Requirements . . . . .	7.09-5
	[c] CAFA Applies to Suits with More Than 100 Plaintiffs . . . . .	7.09-9
	[4] Changes in Rules When Removing Class Actions . . . . .	7.09-11
	[5] Appellate Review of Remand Orders . . . . .	7.09-11
§ 7.10	Settlements of Class Actions . . . . .	7.10-1
	[1] Overview . . . . .	7.10-1

	[2] Judicial Scrutiny of Class Action Settlements Under CAFA . . . . .	7.10-1
	[3] Enhanced Judicial Scrutiny of Class Action Settlements Generally . . . . .	7.10-2
	[4] Required Notice of Class Settlement . . . . .	7.10-3
§ 7.11	Canadian Pharmaceutical and Medical Device Class Action . . . . .	7.11-1
	[1] Overview . . . . .	7.11-1
	[2] Certification Criteria . . . . .	7.11-2
	[a] “Identifiable Class” . . . . .	7.11-3
	[b] “Common Issues” Requirement . . . . .	7.11-4
	[c] “Preferable Procedure” . . . . .	7.11-4
	[d] Adequate “Representative Plaintiff” . . . . .	7.11-5
	[3] Settlement Considerations—Opt-In vs. Opt-Out Classes . . . . .	7.11-6

## CHAPTER 8

### Non-Manufacturer Defendants in Drug and Medical Device Litigation

§ 8.01	Introduction . . . . .	8.01-2
§ 8.02	Commercial Distributors . . . . .	8.02-1
	[1] General Rule of Strict Liability . . . . .	8.02-1
	[2] <i>Restatement (Third)</i> Position . . . . .	8.02-6
	[3] Statutory Exceptions to Strict Liability . . . . .	8.02-7
§ 8.03	Pharmacists . . . . .	8.03-1
	[1] Majority Rule Rejecting Product Liability Claims Against Pharmacists for Prescribed Drugs . . . . .	8.03-1
	[2] Minority Rule Allowing Product Liability Claims Against Pharmacists . . . . .	8.03-18
	[3] Exceptional Circumstances Justifying Imposition of Liability on Pharmacists . . . . .	8.03-22
	[a] Obvious Inadequacies on Face of Prescription/Failure to Label Properly . . . . .	8.03-23
	[b] Voluntary Assumption of Duty to Warn . . . . .	8.03-24
	[c] Specific Knowledge of the Characteristics of a Patient/Customer . . . . .	8.03-26

## TABLE OF CONTENTS

xv

	[d] Failure to Warn of Adverse Interaction of Two Prescribed Drugs . . . . .	8.03-27
	[e] Dispensing Without Valid Renewal Prescription. . . . .	8.03-27
	[f] Failure to Provide FDA-Mandated Materials . . . . .	8.03-28
§ 8.04	Bulk and Component Part Sellers . . . . .	8.04-1
	[1] General Rule. . . . .	8.04-1
	[2] Federal Law Considerations. . . . .	8.04-3
	[3] Common Law Considerations . . . . .	8.04-6
§ 8.05	Hospitals . . . . .	8.05-1
	[1] Strict Liability. . . . .	8.05-1
	[a] <i>Restatement</i> Position and the Sale-Service Distinction . . . . .	8.05-1
	[b] Implied Warranty. . . . .	8.05-7
	[2] Public Policy Based Rationales for Limiting Hospital Product Liability . . . .	8.05-10
	[3] Informed Consent. . . . .	8.05-13
	[a] No Separate Duty . . . . .	8.05-13
	[b] Assumption of Duty . . . . .	8.05-18
	[4] Negligence . . . . .	8.05-20
	[5] Miscellaneous . . . . .	8.05-21
§ 8.06	Physicians and Similar Health Care Providers . . . .	8.06-1
	[1] Strict Liability/Breach of Implied Warranty. . . . .	8.06-1
	[2] Informed Consent. . . . .	8.06-6
	[a] FDA Regulatory Status . . . . .	8.06-6
	[b] Conflict Of Interest . . . . .	8.06-8
§ 8.07	Participants in Clinical Trials. . . . .	8.07-1
	[1] Monitoring . . . . .	8.07-1
	[2] Conflicts of Interest . . . . .	8.07-3
	[3] Product Liability. . . . .	8.07-4
§ 8.08	Promoters and Co-Promoters . . . . .	8.08-1
	[1] Wrongful Marketing or Promotion . . . . .	8.08-1
	[2] First Amendment Defense . . . . .	8.08-5
	[3] Co-Promoters . . . . .	8.08-7
§ 8.09	Original Patent Holders and Inventors. . . . .	8.09-1
§ 8.10	The Food and Drug Administration. . . . .	8.10-1
§ 8.11	Parents, Subsidiaries and Successors . . . . .	8.11-1
§ 8.12	Manufacturer Sales Representatives and Other Personnel. . . . .	8.12-1
§ 8.13	Publishers. . . . .	8.13-1
§ 8.14	Reprocessors . . . . .	8.14-1

## CHAPTER 9

### Issues in the Management of the Litigation

§ 9.01	Overview .....	9.01-3
§ 9.02	Procedural Aggregation.....	9.02-1
	[1] Initiation of Claims .....	9.02-1
	[2] Joinder of Plaintiffs .....	9.02-4
§ 9.03	Collateral Estoppel .....	9.03-1
§ 9.04	Removal from State Court to Federal Court....	9.04-1
	[1] Introduction.....	9.04-1
	[2] General Principles of Removal .....	9.04-1
	[3] Removal in Diversity Cases.....	9.04-3
	[4] Removal in Federal Question Cases .....	9.04-11
	[5] Federal Officer Removal .....	9.04-15
§ 9.05	Multidistrict Litigation .....	9.05-1
	[1] The Commencement of Multidistrict Litigation .....	9.05-1
	[2] Requirement that Actions to be Transferred Have Common Questions of Fact.....	9.05-7
	[a] All Actions Before the Panel Must Have One or More Questions of Fact in Common .....	9.05-7
	[b] The Questions of Fact in Common Must Lend Themselves to Resolution Through Centralization .....	9.05-8
	[c] Commonality Cannot Be Insufficiently Complex .....	9.05-9
	[d] Transfer Must Be for the Convenience of the Parties and Witnesses .....	9.05-10
	[e] Transfer Must Promote the Just and Efficient Conduct of Pretrial Proceedings.....	9.05-12
	[3] Remand of Actions at Suggestion of Transferee Court.....	9.05-14
	[4] Discovery Issues in Multidistrict and Multi-Plaintiff Proceedings .....	9.05-15
	[a] Introduction—The Beginning of a Multidistrict Litigation .....	9.05-15
	[b] Discovery of Defendants.....	9.05-17
	[i] Document Preservation and Production .....	9.05-17
	[ii] Other Discovery Issues.....	9.05-20
	[c] Discovery of Plaintiffs.....	9.05-23

## TABLE OF CONTENTS

xvii

	[d] Case-Specific Expert Discovery Within an MDL . . . . .	9.05-29
	[e] Protecting Trade Secrets and Other Confidential Information . . . . .	9.05-31
	[i] Drafting a Confidentiality Order . . . . .	9.05-34
	[ii] Breach of a Confidentiality Order . . . . .	9.05-41
§ 9.06	Discovery of the FDA . . . . .	9.06-1
§ 9.07	Relations Between State and Federal Courts . . . . .	9.07-1
	[1] Introduction . . . . .	9.07-1
	[2] The All Writs Act and the Anti-Injunction Act . . . . .	9.07-2
	[3] Injunctions in Aid of Jurisdiction . . . . .	9.07-2
	[4] Injunctions to Protect a Federal Court Judgment . . . . .	9.07-5

## CHAPTER 10

### Expert Witnesses

§ 10.01	Introduction . . . . .	10.01-2
§ 10.02	Types of Experts . . . . .	10.02-1
§ 10.03	Discovery and Evaluation of Experts . . . . .	10.03-1
	[1] Introduction . . . . .	10.03-1
	[a] Federal Rules Relating to Discovery of Experts . . . . .	10.03-2
	[b] State Rules Relating to Discovery of Experts . . . . .	10.03-4
	[c] Discovery of Draft Expert Reports and Counsel's Communications with Experts . . . . .	10.03-7
	[d] Discovery of Counsel's Communications with the Expert . . . . .	10.03-10
	[2] Protecting Experts from Unnecessary Disclosure . . . . .	10.03-12
	[a] Communications between Counsel and Experts . . . . .	10.03-12
	[b] Communications among Experts . . . . .	10.03-13
	[c] Withdrawal of the Testifying Expert . . . . .	10.03-13
	[d] Protective Orders . . . . .	10.03-15
	[3] Expert Witness Evaluation Tools . . . . .	10.03-16
	[a] Expert Interrogatories . . . . .	10.03-16

	[b] Expert Depositions and Prior Testimony . . . . .	10.03-17
	[c] Journals and Publications . . . . .	10.03-17
	[d] Expert Databases . . . . .	10.03-17
	[e] Actions by the Office of Research Integrity and the Office for Human Research Protections . . . . .	10.03-18
	[f] Other Experts . . . . .	10.03-19
	[g] Documents Produced in the Litigation . . . . .	10.03-19
	[h] The Industry Client . . . . .	10.03-19
§ 10.04	Admissibility of Expert Testimony . . . . .	10.04-1
	[1] Introduction . . . . .	10.04-1
	[2] <i>Daubert</i> Experience in Drug and Medical Device Litigation . . . . .	10.04-4
	[a] Expert Opinions Based on Epidemiological Studies and Other Human Studies . . . . .	10.04-4
	[b] Expert Opinions Based on Case Reports and Adverse Event Reports . . . . .	10.04-7
	[c] Expert Opinions Based on Animal Studies . . . . .	10.04-9
	[d] Expert Opinions Based on Similar Drugs . . . . .	10.04-11
	[e] Differential Diagnosis as a Methodology for Proving Causation . . . . .	10.04-12
	[f] Expert Opinions Based on Regulatory Actions . . . . .	10.04-16
	[3] State Law Bases for Admissibility of Expert Testimony . . . . .	10.04-16
§ 10.05	Challenges to Qualifications . . . . .	10.05-1
§ 10.06	Expert Testimony on Regulatory Issues . . . . .	10.06-1

## CHAPTER 11

### Trial Issues

§ 11.01	Common Evidentiary Issues at Trial . . . . .	11.01-3
	[1] Admissibility of FDA-Related Evidence . . . . .	11.01-3
	[a] Manufacturer-Specific Regulatory History Documents . . . . .	11.01-3
	[b] FDA Reports . . . . .	11.01-20
	[c] FDA Correspondence . . . . .	11.01-22

## TABLE OF CONTENTS

xix

	[d] Adverse Drug and Medical Device Reports . . . . .	11.01-24
	[e] Evidence of Misstatements to the FDA . . . . .	11.01-30
	[f] Other FDA Evidence . . . . .	11.01-33
[2]	Non-FDA Evidentiary Exclusion Issues . . . . .	11.01-37
	[a] Subsequent Remedial Measures . . . . .	11.01-37
	[b] Similar Incidents . . . . .	11.01-45
	[c] Financial Relationships with Physicians . . . . .	11.01-52
	[d] Notes of Telephone Calls by Sales Representatives . . . . .	11.01-53
	[e] Corporate Motive, State of Mind, and Intent . . . . .	11.01-53
	[f] Warnings, Marketing, and Other Information That Does Not Reach the Prescribing Physician . . . . .	11.01-62
	[g] Foreign Regulatory Proceedings and Decisions . . . . .	11.01-64
	[h] Ghostwriting . . . . .	11.01-67
	[i] Other Evidentiary Issues . . . . .	11.01-68
[3]	FDA Experts . . . . .	11.01-80
§ 11.02	Bifurcation and Consolidation . . . . .	11.02-1
	[1] Bifurcation . . . . .	11.02-1
	[a] How the Courts View Bifurcation . . . . .	11.02-1
	[b] Types of Bifurcation . . . . .	11.02-3
	[i] General Causation . . . . .	11.02-3
	[ii] Liability . . . . .	11.02-4
	[iii] Damages . . . . .	11.02-5
	[iv] Miscellaneous . . . . .	11.02-5
	[c] Arguments for Bifurcation . . . . .	11.02-5
	[i] Judicial Economy . . . . .	11.02-5
	[ii] Prejudice . . . . .	11.02-6
	[d] Arguments Against Bifurcation . . . . .	11.02-7
	[i] Sterile Environment . . . . .	11.02-7
	[ii] Constitutional Limitations . . . . .	11.02-7
	[e] Bifurcation of Punitive Damages . . . . .	11.02-9
	[2] Consolidation . . . . .	11.02-12
§ 11.03	Punitive Damages . . . . .	11.03-1
	[1] How the States View Punitives . . . . .	11.03-1
	[2] Constitutional Standards Governing Punitive Damages After <i>State Farm</i> . . . . .	11.03-23
	[a] Reprehensibility . . . . .	11.03-24
	[b] The Range of Acceptable Punitive to Compensatory Damages Ratios . . . . .	11.03-33

[c]	The “Comparable Civil Penalties” Assessment Is Narrowed . . . . .	11.03-51
[d]	Evidentiary Issues After <i>State Farm</i> . . .	11.03-54
[i]	Evidence of Out-of-State Conduct Admissible Only If a “Nexus” to the Harm in the Action Exists . . . . .	11.03-54
[ii]	Limited Relevance of Evidence of Conduct Injurious to Nonparties . . . . .	11.03-58
[iii]	Evidence of Dissimilar Conduct Is Barred . . . . .	11.03-62
[iv]	Net Worth May be Considered, But Cannot Justify an Otherwise Unconstitutional Award . . . . .	11.03-64
[v]	Expert Testimony on the Amount of Punitive Damages Is Usually Prohibited . . . . .	11.03-68
[e]	Conclusion . . . . .	11.03-69

<b>INDEX</b> . . . . .	I-1
------------------------	-----